Automatiqc® Medical Writing Technology

Innovative AI, cloud-based application to aid in quick and efficient document authoring

We appreciate the innovative spirit of MMS in enabling us to meet important milestones. Excellent job!
SVP, Research & Development
Biotechnology Sponsor

Free up resource time, improve quality, and bring efficiencies to the medical and regulatory writing process

Automatiqc® is a cloud-based solution that utilizes robotic process automation (RPA), a form of artificial intelligence (AI), to apply the required document formatting and style conventions. This frees up writers to focus on the key messaging, stakeholder alignment, and other key elements  that are most critical to the medical and regulatory writing process.

Additional key benefits of Automatiqc include:

  • Removes the burden of style and formatting from the regulatory or medical writer, saving time for critical data elements
  • Built-in set of rules that can be customized to meet any internal company or external audience document style requirements
  • Compounding efficiencies with document amendments, improving the quality of documents and reduces effort for the review and QC steps in subsequent drafts or document amendments
  • Complementary: processed documents are compatible with other tools, including PleaseReview, Veeva RIM and many others
  • Easy output provided in tracked changes for greater visibility to the writer

With this innovative medical writing technology, Automatiqc users are now able to focus where they can bring the greatest value – to the science of Medical & Regulatory Writing.

Get in touch to request a demo of Automatiqc!

Suggested For You

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 16th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today 

perspectives

January 20th, 2026

Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

perspectives

January 13th, 2026

Making Clinical Trial Technology Work in Practice